MiR-192 serving as specificity biomarker for early diagnosis of diabetic kidney disease and application of MiR-192

A technology of diabetic nephropathy, mir-192, applied in miR-192 as a specific biomarker for early diagnosis of diabetic nephropathy and its application field, can solve the problem of glomerular function decline, slow down DKD, glomerular filtration rate decline and other problems to achieve high sensitivity and specificity

Inactive Publication Date: 2017-05-17
天津医科大学代谢病医院
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the main standard for the diagnosis of DKD is to measure the 24-hour urinary protein quantification or the urinary microalbuminuria excretion rate in the overnight period. However, once microalbuminuria is detected clinically, substantial damage to the kidneys already exists, and the glomerular function will be progressive. Irreversible declin...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MiR-192 serving as specificity biomarker for early diagnosis of diabetic kidney disease and application of MiR-192
  • MiR-192 serving as specificity biomarker for early diagnosis of diabetic kidney disease and application of MiR-192
  • MiR-192 serving as specificity biomarker for early diagnosis of diabetic kidney disease and application of MiR-192

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Expression and clinical significance of microRNA192 in serum of patients with diabetic nephropathy at different stages

[0034] Materials and Methods

[0035] 1 reagent

[0036] 1.1 Source of cases

[0037] All subjects in the test group were from inpatients diagnosed with T2DM who visited the Metabolic Disease Hospital of Tianjin Medical University from July 2015 to March 2016, a total of 230 cases; the subjects in the healthy control group came from the physical examination of Konggang Hospital, General Hospital of Tianjin Medical University center. 92 cases of simple diabetes, 87 cases of early nephropathy, 51 cases of clinical nephropathy, 53 cases of healthy controls.

[0038] 1.2 Experimental materials

[0039] Trizol LS Reagent, chloroform (CHCl3), diethyl pyrocarbonate (DEPC), absolute ethanol, isopropanol (analytical grade), Mir-X miRNA First-stand Synthesis Kit, Mir-X miRNA qRT-PCR SYBR kit, RNase-free water (dilute the DEPC stock solution with ...

Embodiment 2

[0136] Example 2 The expression of miRNA-192 in the urine of patients with diabetic nephropathy at different stages and its correlation with the expression in the blood of the same individual

[0137] 1 reagent

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention creatively provides miR-192 serving as a specificity biomarker for early diagnosis of a diabetic kidney disease and application of the MiR-192. The adopted technical scheme is as follows: application of the miR-192 in the serum to the early clinical specificity diagnosis of the diabetic kidney disease uses qRT-PCR to detect miRNA-192 in the serum to diagnose the diabetic kidney disease; application of the miR-192 in the urine to the early clinical specificity diagnosis of the diabetic kidney disease uses qRT-PCR to detect miRNA-192 in the urine to diagnose the diabetic kidney disease, a critical point of the miRNA-192 used for diagnosing the early diabetic kidney disease is provided, application of the miRNA marker is used to prepare an early diagnosis agent or kit for detecting the diabetic kidney disease, and application of the miRNA marker is used to prepare an early diagnosis agent or kit for detecting the diabetic kidney disease. A novel diagnosis means is provided for the clinical diagnosis of the diabetic kidney disease, and the miR-192 and the application of the miR-192 have certain potential clinical values for the adjuvant treatment and the course monitoring of the diabetic kidney disease (DKD).

Description

technical field [0001] The present invention relates to the application of miR-192 as a specific biomarker in the early diagnosis of diabetic nephropathy. [0002] technical background [0003] Diabetic kidney disease (DKD), also known as diabetic nephropathy (DN), is a common microvascular complication in patients with diabetes mellitus (DM). The kidney damage caused by it involves not only blood vessels, glomeruli, and renal tubules, but also almost all renal structures such as renal interstitium and podocytes. [0004] At present, the main standard for the diagnosis of DKD is to measure the 24-hour urinary protein quantification or the urinary microalbuminuria excretion rate in the overnight period. However, once microalbuminuria is detected clinically, substantial damage to the kidneys already exists, and the glomerular function will be progressive. Irreversible decline; clinically, some DM patients with urinary albumin within the normal range have actually experienced a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/68
CPCC12Q1/6883C12Q2600/158C12Q2600/178
Inventor 于珮周赛君
Owner 天津医科大学代谢病医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap